期刊文献+

多柔比星长效注射微球的评价和对小鼠肿瘤的抑制作用 被引量:3

CHARACTERIZATION OF DOXORUBICIN LOADED MICROSPHERES AND ITS TUMOR INHIBITORY EFFECT IN MICE
下载PDF
导出
摘要 主要考察了多柔比星(Dox)微球的理化性质、释放特性及其对荷瘤小鼠的抑制作用.以乳酸-羟乙酸共聚物(PLGA)为载体材料,用复乳法(w/o/w)制备载Dox长效注射微球;考察粒径大小、外观、包封率、载药量等理化性质;用紫外分光光度法检测了体外释放溶液中的药物含量,以荷Lewis肺癌小鼠的肿瘤质量和体积为指标观察Dox微球(Dox-MS)瘤内注射给药后的抗肿瘤活性.制备得到的微球球形圆整、分散性好,平均粒径为82.94μm,包封率为92.67%,载药量为9.12%.微球体外第1天释放30.24%,20 d累积释放91.85%.给药8 d后,Dox微球瘤内注射给药组与对照组相比肿瘤平均体积明显减小,抑瘤率与对照组相比具有极显著性差异(P<0.01),但与Dox溶液静脉、瘤内给药组相比无显著性差异.因此Dox微球对小鼠体内Lewis肺癌具有较好的抑制作用,其抑瘤效果与瘤内注射相同剂量的Dox溶液相当,但局部刺激性较小. The doxorubicin(Dox)--loaded microsphere was prepared, and its physical characteristics, in vitro release behavior and tumor inhibitory effect in mice were evaluated. The microspheres were prepared with poly(lactic-co-glycolic acid) (PLGA) as carrier material by double emulsion (w/o/w) method. Physical characteristics of microspheres, such as mean diameter, morphology, drug entrapment efficiency and loading percent were evaluated. The in vitro release content was determined by ultraviolet spectrophotometry. The volume and weight of tumors were evaluated to determine the antitumor effect of Dox-loaded microspheres injected intratumorally(i, t. ) in mouse with Lewis lung cancer. Microspheres had good shape and dispersive quality. The mean diameter was 82.94 μm, drug entrapment efficiency 92.67%, and loading percentage 9.12%. The cumulative release content was 30.24% on day 1, and 91.85% on day 20. The mean tumor volume of Dox-loaded microspheres (Dox-MS) group was smaller than control. There was significant difference between Dox-MS group and control in tumor growth inhibition(P〈0.01), but no difference among Dox-MS, Dox i.v. and Dox i. t. groups. Therefore, Dox-MS had good growth inhibitory effect on Lewis cancer in mice, which was similar to that caused by Dox solution i. t.
出处 《北京师范大学学报(自然科学版)》 CAS CSCD 北大核心 2008年第3期287-290,共4页 Journal of Beijing Normal University(Natural Science)
关键词 多柔比星 微球 聚乳酸-羟基乙酸共聚物(PLGA) LEWIS肺癌 抑瘤率 Doxorubicin microspheres poly ( lactide-glycolide acid) (PLGA) Lewis cancer tumourgrowth inhibition
  • 相关文献

参考文献9

  • 1Abraham S A,Waterhouse D N,Mayer L D,et al.The liposomal formulation of doxorubicin[J].Methods Enzymol,2005,391:71.
  • 2Cleland J L.Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines[J].Biotechnol Prog,1998,14:102.
  • 3彭方兴,严律南,林琦远,白绍槐,张旋波.阿霉素乙基纤维素微球肝动脉栓塞化疗的实验研究[J].中国普外基础与临床杂志,2001,8(3):138-140. 被引量:6
  • 4Tan Eng Chew,Lin Rongyi,Wang Chihwa.Fabrication of double-walled microspheres for the sustained release of doxorubicin[J].J Colloid Interface Sci,2005,291(1):135.
  • 5赵瑞玲,丁红,谢茵.阿霉素聚乳酸微球的制备及体外释药特性研究[J].中国医院药学杂志,2004,24(2):74-75. 被引量:24
  • 6Lin Rongyi,Ng L S,Wang Chihwa.In vitro study of anticancer drug doxorubicin in PLGA-based micro-particles[J].Biomaterials,2005,26(21):4476.
  • 7刘同刚,唐敏章,金发光.加温敏感阿霉素脂质体治疗小鼠荷Lewis肺癌[J].第四军医大学学报,2003,24(4):335-337. 被引量:11
  • 8Yoshimoto Y,Kawada M,Ikeda D,et al.Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo[J].Int J Immunopharmacol,2005,5:281.
  • 9Lesniak M S,Upadhyay U,Goodwin R,et al.Local delivery of doxorubicin for the treatment of malignant brain tumors in rats[J].Anticancer Res,2005,25:3825.

二级参考文献13

  • 1杨继金,朱永法.大白鼠转移性肝癌模型的制作[J].中华放射学杂志,1993,27(2):122-123. 被引量:43
  • 2王亚敏,石庭森,蒲永林,朱建纲,赵延乐.顺铂壳聚糖微球的制备及特性研究[J].药学学报,1996,31(4):300-305. 被引量:24
  • 3盛洁,魏树礼.阿霉素毫微球制剂的研究进展[J].国外医药(合成药.生化药.制剂分册),1996,17(1):34-37. 被引量:3
  • 4张志荣,王丹,廖方义,廖工铁.肝动脉栓塞米托蒽醌乙基纤维素微球的研究[J].药学学报,1996,31(8):626-631. 被引量:15
  • 5陶忠华.聚乳酸类生物降解聚合物在控释制剂中的应用[J].药学进展,1996,20(4):197-203. 被引量:8
  • 6[1]Shimose S, Sugita T, Nitta Y, Kubo T, Ikuta Y, Murakami T. Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma [J]. Int J Oncol,2001;19(3): 585-589.
  • 7[2]Nakao K, Otsuki Y, Akao Y, Ito Y, Marukawa O, Tachibana S, Kawakami M, Sasaki S. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis [J]. Med Electron Microsc,2000;33(1): 44-50.
  • 8[3]Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure [J]. J Pharmacol Exp Ther, 2002;300(3): 862-867.
  • 9[4]Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: Evidence for selective impairment of myofibrillar creatine kinase [J]. Br J Pharmacol, 2002;135(3): 581-588.
  • 10[5]Safra T, Muggia F, Jeffers S, Tsao-wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg·m-2 [J]. Ann Oncol, 2000;11(8): 1029-1033.

共引文献37

同被引文献37

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部